Merck And Co Inc Drug Patent Portfolio
Merck And Co Inc owns 1 orange book drug protected by 6 US patents Given below is the list of Merck And Co Inc's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5691336 | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists | 04 Sep, 2019 | Expired |
| US5691336 | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists | 04 Mar, 2019 | Expired |
| US5716942 | Treatment of migraine with morpholine tachykinin receptor antagonists | 10 Feb, 2015 | Expired |
| US5512570 | Treatment of emesis with morpholine tachykinin receptor antagonists | 04 Mar, 2014 | Expired |
| US5538982 | Medical use for tachykinin antagonists | 23 Jul, 2013 | Expired |
| US7214692 | Medical use for tachykinin antagonists | 18 Sep, 2012 | Expired |
Latest Legal Activities on Merck And Co Inc's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Merck And Co Inc.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 08 Feb, 2024 | US8258132 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 18 Feb, 2020 | US8258132 |
|
Expire Patent
Critical
| 05 Jun, 2015 | US7214692 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 04 Sep, 2012 | US8258132 |
|
Recordation of Patent Grant Mailed
Critical
| 04 Sep, 2012 | US8258132 |
|
Issue Notification Mailed
Critical
| 15 Aug, 2012 | US8258132 |
|
Application Is Considered Ready for Issue
Critical
| 01 Aug, 2012 | US8258132 |
| Dispatch to FDC | 01 Aug, 2012 | US8258132 |
|
Issue Fee Payment Received
Critical
| 30 Jul, 2012 | US8258132 |
|
Issue Fee Payment Verified
Critical
| 30 Jul, 2012 | US8258132 |
| Printer Rush- No mailing | 14 Jun, 2012 | US8258132 |
| Mail Miscellaneous Communication to Applicant | 14 Jun, 2012 | US8258132 |
| Miscellaneous Communication to Applicant - No Action Count | 12 Jun, 2012 | US8258132 |
|
Pubs Case Remand to TC
Critical
| 07 Jun, 2012 | US8258132 |
|
Mail Notice of Allowance
Critical
| 03 May, 2012 | US8258132 |
Merck And Co Inc's Drug Patent Litigations
Merck And Co Inc's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jul 26, 2005, against patent number US7214692. The petitioner , challenged the validity of this patent, with Russell Michael Hagan et al as the respondent. Click below to track the latest information on how companies are challenging Merck And Co Inc's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US5691336 | December, 2014 |
Terminated-Denied
(25 Jun, 2015)
| Merck Sharp & Dohme Corp. | Apotex Inc. |
| US7214692 | July, 2005 |
Decision
(18 Jan, 2006)
| Russell Michael Hagan et al | |
Merck And Co Inc's Family Patents
Merck And Co Inc Drug List
Given below is the complete list of Merck And Co Inc's drugs and the patents protecting them.
1. Emend
Emend is protected by 6 patents, out of which all have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US5691336
(Pediatric)
| Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
04 Sep, 2019
(5 years ago)
| Expired |
| US5691336 | Morpholine compounds are prodrugs useful as tachykinin receptor antagonists |
04 Mar, 2019
(5 years ago)
| Expired |
| US5716942 | Treatment of migraine with morpholine tachykinin receptor antagonists |
10 Feb, 2015
(9 years ago)
| Expired |
| US5512570 | Treatment of emesis with morpholine tachykinin receptor antagonists |
04 Mar, 2014
(10 years ago)
| Expired |
| US5538982 | Medical use for tachykinin antagonists |
23 Jul, 2013
(11 years ago)
| Expired |
| US7214692 | Medical use for tachykinin antagonists |
18 Sep, 2012
(12 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Emend's drug page